Keyphrases
Immune Cells
88%
Cell State
66%
Single-cell Transcriptomics
66%
Immune Suppression
66%
Rhabdomyosarcoma
66%
Mode of Action
66%
Cancer Organoids
66%
Engineered T Cells
66%
Patient Outcomes
66%
Engager
44%
Solid Tumors
44%
T Cells
44%
Cellular Immunotherapy
44%
Transcriptomics
31%
Differentiation State
28%
Behavioural Clusters
22%
Therapeutic Modes
22%
Serial Killing
22%
Phenotypic Heterogeneity
22%
Cell Concept
22%
Dynamic Interaction
22%
Patient-derived
22%
Cell Therapy
22%
Type I Interferon
22%
In Vitro Model
22%
Targeted Cells
22%
Specific Genes
22%
Gene Signature
22%
Solid Tumor Targeting
22%
T Cell Activation
22%
Blood Cancer
22%
Metabolomics
22%
Cell Culture
22%
Tumor Organoids
22%
Organoids
22%
Myogenic Differentiation
19%
Cellular Differentiation
19%
Tumor Niche
9%
Soft Tissue Malignancy
9%
TIGIT
9%
Rhabdomyosarcoma Cells
9%
Treatment Regimen
9%
Pediatric Rhabdomyosarcoma
9%
Intensive Care Medicine
9%
Immunosuppressive Microenvironment
9%
Risk Stratification
9%
T Cell Depletion
9%
Immune Microenvironment
9%
Tumor Differentiation
9%
Clinical High Risk
9%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Transcriptomics
77%
Cellular Differentiation
66%
Immunity
66%
TIGIT
33%
Messenger RNA
33%
Phenotypic Heterogeneity
11%
Cell Function
11%
Metabolome
11%
Gene Signature
11%
Immunocompetent Cell
11%
Interferon Type I
11%
Medicine and Dentistry
Rhabdomyosarcoma
66%
Transcriptomics
66%
Immunosuppressive Treatment
66%
Immunocompetent Cell
66%
Neoplasm
16%
Cell Differentiation
16%
Immunosuppressive Drug
8%
Rhabdomyosarcoma Cell
8%
Risk Stratification
8%
Cancer
8%
T Cell
8%
Pediatrics
8%
Tumor Differentiation
8%
Messenger RNA
8%
Immunity
8%